Sutro Biopharma Inc expected to post a loss of 76  cents a share - Earnings Preview

Sutro Biopharma

06/05/2022 19:30

* Sutro Biopharma Inc  STRO.OQ   STRO.O  is expected to show
a
fall in quarterly revenue when it reports  results on May 9
(estimated). 
    * The South San Francisco California-based  company is
expected to
report  a 28.6% decrease in revenue to $10.466 million from
$14.66 million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Sutro Biopharma Inc
is
for a loss of 76 cents per share. For the same quarter last
year, the company reported a loss of 66 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sutro
Biopharma
Inc is $30​, above​ its last closing price of $6.06. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.70       -0.69      -0.83     Missed  -20.5
 Sep. 30 2021  -0.65       -0.65      -0.67     Missed  -2.9
 Jun. 30 2021  -0.41       -0.41      -0.13     Beat    68.6​
 Mar. 31 2021  -0.63       -0.60      -0.66     Missed  -9.4
 ​​Dec.        -0.44       -0.57      -1.48     Missed  -159.6
 31 2020                                                
 Sep. 30 2020  -0.45       -0.51      0.45      Beat    188.7​
 Jun. 30 2020  -0.64       -0.64      -0.59     Beat    8.4
 Mar. 31 2020  -0.66       -0.69      -0.84     Missed  -22
 This summary was machine generated May 6 at 18:30 GMT.  All
figures in US dollars  unless otherwise stated